FORE Biotherapeutics vs Variantyx
FORE Biotherapeutics vs Variantyx, compared side by side on 21 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: FORE Biotherapeutics is on 56/100 and Variantyx on 63/100.
Where each one leads
FORE Biotherapeutics
- headcount growth: +8.2% against +5.0%
- funding raised: $232M against $74.5M
Variantyx
- our overall score: 63/100 against 56/100
- agent readiness: 45/100 against 37/100
- headcount: 226 against 56
- LinkedIn following: 23,938 against 4,584
At a glance
| Measure | FORE Biotherapeutics | Variantyx |
|---|---|---|
| What it is | Precision oncology company developing cancer therapies guided by proprietary functional genomics. | Variantyx is a precision medicine company offering comprehensive genomic testing solutions for rare genetic disorders, reproductive health, and oncology. |
| Category | Healthcare, Drug Development, Genomics, Next Generation Sequencing | Healthcare, Genomics, Sequencing, Genetics |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2011 | 2014 |
| Headquarters | Philadelphia, United States | Framingham, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | FORE Biotherapeutics | Variantyx |
|---|---|---|
| Employees | 56 | 226 |
| Headcount growthLast 12 months | +8.2% | +5.0% |
| Total funding | $232M | $74.5M |
| Latest round | Series D-2 Extension | Series D |
| Valuation | $75.0M | Not published |
| LinkedIn followers | 4,584 | 23,938 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | FORE Biotherapeutics | Variantyx |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 56/100 | 63/100 |
| Traction | 58/100 | 59/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 38/100 | 33/100 |
| Quality | 55/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (37/100) | D (45/100) |
| Domain ratingLink authority, 0-100 | 35/100 | 32/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | FORE Biotherapeutics | Variantyx |
|---|---|---|
| CDN | Not detected | Cloudflare |
| CMS | WordPress | WordPress |
| Frameworks | Jquery | Jquery |
| Analytics | Not detected | Google Analytics 4 |
FORE Biotherapeutics vs Variantyx: common questions
Which is better, FORE Biotherapeutics or Variantyx?
On our 0-100 score Variantyx rates higher (63/100 against 56/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 21 data points above: read the rows that match what you are buying for.
How do FORE Biotherapeutics and Variantyx compare on the numbers?
FORE Biotherapeutics leads on headcount growth (+8.2% against +5.0%), funding raised ($232M against $74.5M). Variantyx leads on our overall score (63/100 against 56/100), agent readiness (45/100 against 37/100), headcount (226 against 56), LinkedIn following (23,938 against 4,584).
Read the full FORE Biotherapeutics review and pricing or the Variantyx review and pricing. You can also browse other FORE Biotherapeutics alternatives we track.